Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation

Pharmacotherapy

Volumn 21, Issue 7, 2001, Pages 778-796

  Matheny, Christopher J ^a   Lamb, Matthew W ^a   Brouwer, Kim L R ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BIRICODAR; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; COLCHICINE; CYCLOSPORIN; DIGOXIN; DOXORUBICIN; DOXORUBICINOL; ELACRIDAR; ERYTHROMYCIN; GLYCOPROTEIN P; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LANIQUIDAR; LOPERAMIDE; MORPHINE; OC 144 093; OCTREOTIDE; PACLITAXEL; PROPAFENONE; QUINIDINE; RIFAMPICIN; TALINOLOL; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; XR 9051; ZOSUQUIDAR;

CANCER; CARDIOTOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG MARKETING; DRUG MECHANISM; DRUG TRANSPORT; HUMAN; HYPERICUM PERFORATUM; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; HUMANS; KIDNEY; LIVER; P-GLYCOPROTEIN;

EID: 0034964222     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.9.778.34558     Document Type: Review

References (254)

1. P-glycoprotein and multidrug resistance
2. Molecular targets in oncology: Implications of the multidrug resistance gene
3. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption
4. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
5. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein
6. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs
7. Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein
8. 2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2
9. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells
10. Functional characterization of the rat mdr1b encoded P-glycoprotein: Not all inducing agents are substrates
11. Role of P-170 glycoprotein in colchicine brain uptake
12. Grapefruit juice activates P-glycoprotein-mediated drug transport
13. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in MDR1A P-glycoprotein
14. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
15. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML)
16. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
17. Inhibition of the intestinal digoxin absorption and exsorption by quinidine
18. Effect of PSC 833 a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats
19. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
20. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
21. P-glycoprotein-mediated transcellular transport of MDR-reversing agents
22. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism
23. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers
24. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
25. Upregulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment
26. Phorbol ester-induced P-glycoprotein phosphorylation and functionality in the HTB-123 human breast cancer cell line
27. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver
28. Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants
29. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells
30. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells
31. Clinical trials of modulation of multidrug resistance: Pharmacokinetic and pharmacodynamic considerations
32. Active transport of fentanyl by the blood-brain barrier
33. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein
34. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
35. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier
36. Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: The role of P-glycoprotein
37. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study
38. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells
39. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat
40. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells
41. Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: Possible involvement of P-glycoprotein
42. P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule
43. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
44. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
45. Co-administration of cyclosporin enables oral therapy with paclitaxel
46. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in the drug delivery to the brain
47. P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier
48. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cells
49. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
50. Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors
51. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound
52. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans
53. Human P-glycoprotein transports cyclosporin A and FK506
54. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice
55. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
56. Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression
57. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells
58. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats
59. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice
60. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats
61. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo
62. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
63. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
64. The physiological function of drug-transporting P-glycoproteins
65. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
66. Clinical studies with modulators of multidrug resistance
67. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation
68. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
69. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis
70. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer
71. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay
72. Reversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizole
73. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
74. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients
75. Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line
76. Multidrug resistance-modifying components in human plasma with potential clinical significance
77. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats
78. Restoring uptake and retention of daunorubicin and idarubicin in P170- related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833
79. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles
80. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds
81. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein
82. A model for the prediction of digoxin-drug interactions at the renal tubular cell level
83. Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells
84. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs
85. Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells
86. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein
87. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine
88. Progesterone and its metabolites: The potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland
89. Serum can inhibit reversal of multidrug resistance by chemosensitisers
90. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia
91. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog
92. Differentiation between specific and nonspecific effects related to P-glycoprotein inhibition in immortalized rat brain endothelial cells
93. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
94. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
95. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype
96. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin
97. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes
98. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine
99. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine
100. Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines
101. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells
102. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein
103. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
104. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
105. RS-33295-198: A novel, potent modulator of P-glycoprotein-mediated multidrug resistance
106. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
107. Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein
108. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells
109. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
110. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance
111. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
112. SDZ 280-446, a novel semi-synthetic cyclopeptolide: In vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance
113. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
114. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative
115. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein-mediated multidrug resistance
116. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
117. Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway
118. Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver
119. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues
120. Hydroxyethyl cyclosporin A induces and decreases P4503A and P-glycoprotein levels in rat liver
121. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells
122. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers
123. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists
124. Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro
125. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys
126. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells
127. Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone
128. Increased brain P-glycoprotein in morphine tolerant rats
129. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics
130. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line
131. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
132. Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney
133. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
134. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy
135. Multidrug resistance and its reversal
136. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance
137. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
138. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
139. Drug resistance
140. Multidrug resistance: Molecular mechanisms and clinical relevance
141. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
142. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
143. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
144. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
145. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor
146. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
147. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
148. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
149. Biochemistry of multidrug resistance mediated by the multidrug transporter
150. ABC transporters: From microorganisms to man
151. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport
152. Biology of the multidrug resistance-associated protein, MRP
153. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues
154. P-glycoprotein, a gatekeeper in the blood-brain barrier
155. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
156. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption
157. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
158. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice
159. Altered disposition and antinociception of [D-penicillamine(2,5)]enkephalin in mdr1a-gene-deficient mice
160. How does P-glycoprotein recognize its substrates?
161. Transcriptional regulation of multidrug resistance gene expression
162. Transcriptional regulation of multidrug resistance in breast cancer
163. Influence of exogenous RAR alpha gene on MDR1 expression and P-glycoprotein function in human and rodent cell lines
164. Coordination of transcription factors, NF-Y and C/EBP beta, in the regulation of the mdr1b promoter
165. 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1
166. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter
167. Purification and characterization of NF-R2 that regulates the expression of the human multidrug resistance (MDR1) gene
168. Intestinal secretion of drugs: The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
169. Active secretion and enterocytic drug metabolism barriers to drag absorption
170. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa
171. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney
172. Drug metabolism by cytochromes P450 in the liver and small bowel
173. Molecular and physical mechanisms of first-pass extraction
174. Elucidation of the structure of talinolol metabolites in man: Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum
175. Interaction between quinidine and digoxin
176. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
177. Verapamil-rifampin interaction
178. Reduction of bioavailability of verapamil by rifampin
179. Acute heart transplant rejection due to Saint John's wort
180. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin
181. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation
182. Indinavir concentrations and St. John's wort
183. Interaction of a herbal extract from St. John's wort with amitriptyline and its metabolites
184. Hepatobiliary secretion of organic compounds: Molecular mechanisms of membrane transport
185. Bile acid and xenobiotic transporters in liver
186. Molecular pathogenesis of cholestasis
187. Molecular identification and functional characterization of mdr1a in rat cholangiocytes
188. Molecular aspects of hepatobiliary transport
189. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs
190. The anthracycline antineoplastic drugs
191. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice
192. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo
193. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein
194. Relationship between P-glycoprotein expression and cyclosporin A in kidney: An immunohistological and cell culture study
195. Renal secretion of xenobiotics mediated by P-glycoprotein: Importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycytic kidney disease
196. Transepithelial transport of levofloxacin in the isolated perfused rat kidney
197. A physiological function for multidrug-resistant membrane glycoproteins: A hypothesis regarding the renal organic cation-secretory system
198. Renal secretion of organic cations: A multistep process
199. Therapeutic concentrations of cyclosporin A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells
200. The quinidine-digoxin interaction
201. Digoxin-quinidine interaction pharmacokinetic evaluation
202. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)
203. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
204. The digoxin-propafenone interaction: Characterization of a mechanism using renal tubular cell monolayers
205. Digoxin-itraconazole interaction: Possible mechanisms
206. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin
207. Endothelial cells of the brain and other organ systems: Some similarities and differences
208. Transporters and the blood-brain barrier (BBB)
209. The functional role of P-glycoprotein in the blood-brain barrier
210. CNS drug design based on principles of blood-brain barrier transport
211. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine
212. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain
213. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier
214. P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries
215. Brain microvascular and astrocyte localization of P-glycoprotein
216. Effect of GW918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat
217. Passage of a delta-opioid receptor selective enkephalin, [D-penicillamine2,5] enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers
218. 5]enkephalin and two halogenated analogs after intravenous administration
219. 5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration
220. Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats
221. Blood-brain disposition and antinociceptive effects of -D- penicillamine 2,5-enkephalin in the mouse
222. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium
223. Increased drug delivery to the brain by P-glycoprotein inhibition
224. Loss of analgesic effect of morphine due to coadministration of rifampin
225. Pharmacological considerations in the modulation of multidrug resistance
226. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease
227. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies
228. Decay characteristics of HIV-1-infected compartments during combination therapy
229. H1V-1 protease inhibitors are substrates for the MDR1 multidrug transporter
230. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
231. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
232. Age-related changes in T cell surface markers: A longitudinal analysis in genetically heterogeneous mice
233. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
234. Differential activity of P-glycoprotein in normal blood lymphocyte subsets
235. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
236. P-glycoprotein expression and function in circulating blood cells from normal volunteers
237. P-glycoprotein (MDR1 gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection
238. + T cells: A role in cytotoxic effector function
239. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporin A analogs
240. Expression of the mdr1 P-glycoprotein gene: A mechanism of escape from glucocorticoid-induced apoptosis
241. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow
242. The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders
243. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia
244. P-glycoprotein in adult hematologic malignancies
245. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias
246. Human immunodeficiency virus 1-induced expression of P-glycoprotein
247. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
248. Pharmacological insights from P-glycoprotein knockout mice
249. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1
250. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
251. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells
252. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
253. Co-operative binding sites for transported substrates in the multiple drug resistance transporter Mdr1
254. Communication between multiple drug binding sites on P-glycoprotein